OCGN — Ocugen, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1372299 ·
Last close
$1.34
Market Cap
$453.62M
52W High
$2.72
52W Low
$1.27
ADV30
7,263,187
Next earnings
2026-07-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,533,000 | — | -17,839,000 | -19,177,000 | 56,905,000 | 31,855,000 | 51,100,000 |
| Dec 2025 | -193,000 | — | -16,995,000 | -17,706,000 | 43,516,000 | 18,571,000 | 55,682,000 |
| Sep 2025 | 1,752,000 | — | -17,625,000 | -20,051,000 | 57,596,000 | 32,565,000 | 54,063,000 |
| Jun 2025 | 1,373,000 | — | -13,795,000 | -14,739,000 | 53,594,000 | 27,013,000 | 50,542,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,401,000
Investing CF
$-215,000
Financing CF
$53,557,000
CapEx
$-175,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-427,244,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-66,763,000
Pretax Income TTM
$-71,673,000
Interest Exp TTM
$5,223,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,465,000
EBITDA
$-63,870,000
Free Cash Flow
$-33,665,624
Enterprise Value
$455,060,288
Total Cash
$31,855,000
Total Debt
$33,296,000
Shares Out
338,521,856
Trailing EPS
$-0.24
Book Value
$-0.04
ROE
-660.0%
ROA
-68.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,413,000 | -62,916,000 | -67,846,000 | 43,516,000 | 55,682,000 | — | -56,964,000 |
| Dec 2024 | 4,055,000 | -54,757,000 | -54,054,000 | 82,442,000 | 52,810,000 | — | -42,142,000 |
| Dec 2023 | 6,036,000 | -65,531,000 | -63,078,000 | 64,547,000 | 23,983,000 | — | -62,054,000 |
| Dec 2022 | 2,488,000 | -89,071,000 | -86,804,000 | 108,632,000 | 34,651,000 | — | -60,079,000 |
TTM Snapshot
Revenues TTM
$1,136,000
NetIncome TTM
$-12,970,000
OpCashFlow TTM
$0
Assets (Latest)
$82,442,000
Forward EPS
$-0.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| STRO | SUTRO BIOPHARMA, INC. | $453.70M | $27.38 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $455.33M | $8.71 | — |
| AUTL | Autolus Therapeutics plc | $447.12M | $1.68 | — |
| DNA | Ginkgo Bioworks Holdings, Inc. | $463.71M | $8.69 | — |
| LXEO | Lexeo Therapeutics, Inc. | $403.60M | $5.14 | — |
News headlines (Yahoo Finance, 1h cache)
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
2026-05-14 20:30 · Yahoo
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
2026-05-13 11:02 · Yahoo
Ocugen (OCGN) Reports Q1 EPS
2026-05-13 06:21 · Yahoo
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed?
2026-05-09 00:28 · Yahoo
Ocugen (OCGN) Upgraded to Buy: Here's Why
2026-05-08 16:00 · Yahoo
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook
2026-05-06 16:01 · Yahoo
Ocugen Q1 Earnings Call Highlights
2026-05-05 19:27 · Yahoo
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates
2026-05-05 14:00 · Yahoo
Ocugen Provides Business Update with First Quarter 2026 Financial Results
2026-05-05 12:32 · Yahoo
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
2026-05-05 12:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.